Boardroom Alpha
Boardroom Alpha
ACH · Current Report (Form 8-K) · Filed August 10, 2026

Accendra Health Inc — Current Report (Form 8-K)

Form
8-K
Filed
August 10, 2026
Period
Aug 10, 2026
Ticker
ACH
Accession
0001104659-26-092973
Boardroom Alpha · Filing insights

CEO and Director Edward Pesicka will retire by year-end 2026; board evaluating a successor.

About Accendra Health Inc
Market cap
$93M
1Y TSR
−68.4%
3Y TSR
−53.6%
Board grade
C-
Sector
Healthcare
CEO
Edward A Pesicka
Last annual meeting: May 14, 2026 · View full Accendra Health Inc profile →

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 10, 2026

 

Accendra Health, Inc.

(Exact name of registrant as specified in its charter)

 

Virginia

 

001-09810

 

54-1701843

(State or other jurisdiction of
incorporation or organization)
  (Commission File Number)   (I.R.S. Employer Identification No.)

 

4435 Waterfront Drive, Suite 300,
Glen Allen, Virginia

 

23060

(Address of principal executive offices)   (Zip Code)

 

(804) 277-4304
(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange
on which registered
Common Stock, $2 par value per share   ACH   New York Stock Exchange

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 10, 2026, Accendra Health, Inc. (the “Company”) announced that Edward A. Pesicka, President, Chief Executive Officer & Director of the Company, notified the board of directors (the “Board”) of the Company of his intention to retire and step down from the Board by the end of 2026, or such earlier time as a successor is appointed. Mr. Pesicka’s decision to retire is not the result of any disagreement with the Company regarding any matter relating to the Company’s operations, policies or practices. The Board has commenced a process to evaluate and select the candidate to succeed Mr. Pesicka.

 

Item 7.01Regulation FD Disclosure.

 

On August 10, 2026, the Company issued a press release announcing Mr. Pesicka’s intent to retire.

 

The Company is furnishing the press release attached hereto as Exhibit 99.1 pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.
  Description
99.1   Press Release dated August 10, 2026
     
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ACCENDRA HEALTH, INC.
   
August 10, 2026 /s/ Jonathan A. Leon
  Jonathan A. Leon
  Executive Vice President and Chief Financial Officer

 

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Accendra Health Inc (ACH)

Reference

Frequently asked questions

When did Accendra Health Inc file this 8-K?
Accendra Health Inc (ACH) filed this Current Report (Form 8-K) with the SEC on August 10, 2026. The accession number assigned by EDGAR is 0001104659-26-092973.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
CEO and Director Edward Pesicka will retire by year-end 2026; board evaluating a successor. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Accendra Health Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Accendra Health Inc has filed under CIK 75252, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer